In this webinar, Bhavesh Patel and Shrinidhi Chakravarthy of CRA’s Life Sciences Consulting Practice explored how a customized approach could help rare disease (RD) companies identify and maintain RD patients unlocking the true potential of the product and optimizing performance. CRA presented an integrated approach on Market Sizing, Patient Finding, and Patient Tracking for successful RD asset commercialization, which applies at various stages from opportunity assessment and clinical development to commercialization and lifecycle management.
France’s temporary authorisation (ATU) programme: reform implications
The temporary authorisation for use (Autorisation Temporaire d’Utilisation, ATU) programme in France is intended to provide early access to medicines for...